Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02097615
Other study ID # GTSSA02101-298
Secondary ID
Status Completed
Phase Phase 4
First received March 24, 2014
Last updated August 18, 2016
Start date May 2014
Est. completion date December 2014

Study information

Verified date December 2014
Source Universidad de Guanajuato
Contact n/a
Is FDA regulated No
Health authority Mexico: National Council of Science and Technology
Study type Interventional

Clinical Trial Summary

At present research has generated controversy regarding the utility of antiseptics in wound management for diabetic foot ulcers syndrome. However, these studies have been done in tissues and animal models. This study involves the best presently antiseptic for residual effect and low toxicity in an approach to eliminate microorganisms promoters formation of biofilm, contributing to the treatment for accelerated closure the diabetic foot ulcers syndrome .

So it is necessary to determine if irrigation ulcer diabetic foot syndrome with chlorhexidine 0.125 % aqueous solution determines the decrease of the surface to a greater extent than the standard treatment using irrigation with sterile deionized water .


Description:

The present study be made performed at the Hospital General Leon.

Population:

People with Diabetes Mellitus state of Guanajuato.

Universe:

People with diabetes mellitus and diabetic foot syndrome Guanajuato state . sample: Will be evaluated in patients with diabetes mellitus presenting loss of continuity of the skin of the lower limbs and coming to the clinic wound´s of the León General Hospital . This clinic provides services to patients in the state of Guanajuato with diabetic foot syndrome, including them within a multidisciplinary management program .

Calculation of Sample :

72 patients; more eight for lost estimates, 40 patients for each group are required to have a 80 % chance of detecting , with a significance level of 5%, an increase in the primary outcome measure of 5% in the control group and 6 % in group experimental .

Alpha: 5 % Power : 80 %

Inclusion Criteria:

Indistinct gender Patients over 18 years with Diabetes Mellitus and submit ulcer from diabetic foot syndrome not involving tendon , capsule or bone.

With proper state of vascular perfusion.

Exclusion Criteria :

Ulcers in patients with interdigital or difficult to measure the affected surface areas.

Patients not be located at follow-up or wish to stop participating in the study.

Methodology:

Will be invited to participate in the study patients with diabetes mellitus consecutive presented with ulcers plantar to IA or IB grade classification system ulcers , University of Texas, in the area of Clinical wound´s of the Hospital General Leon between Abril and November 2014.

After explaining the study information and check which is understandable , they provide the sheet to be signed informed consent.

Subsequently selected patients will be given a vascular ultrasound to measure the ankle brachial index and determine the absence of vascular compromise.

They carry out their medical history with emphasis on analyzing clinical data , including the characteristics of the ulcer (type of exudate , measured surface area affected , type of tissue involved in the ulcer to its depth ) and biochemical parameters .

Be weighed and measured at the first visit and not having biochemical data are requested to collect this information in subsequent follow-up visit .

They were then treated with the principles of the standard treatment, under the following criteria :

- Remove the ulcer exudate by spraying one of the two ingredients making mechanical drive for 5 minutes, or until completely negative to the visual evidence of exudate.

- Completely remove hyperkeratosis and devitalized tissue from the periphery of the ulcer with cutting material dissection with sterile dressing and drag , until visually eliminate the exudate.

- The treated area is dry and sore

- Two photographs at a distance of 20 cm perpendicular to the ulcer will be taken, covering a 1 square centimeter reference for measuring the area affected by diabetic foot ulcer syndrome.

- The solution so blinded to the ulcer and covered with sterile dressing will be applied for 24 hours .

- The patient will be instructed to continue treatment every 24 hours as follows :

- Sterile dressing will be removed and continuously irrigate for 5 seconds with the ingredient that was assigned .

- Undiscovered for 24 hours , until the next day irrigation dressing area will be placed . Also need to avoid contact with any surface over the affected area until the next assessment .

- Perform the same strategy for 24 hours , and on day 7 will go to the wound clinic to clinical evaluation.

- Every 7 days until complete 6 views, clinical evaluation are performed, irrigation with the selected ingredient and it will take 2 pictures at a distance of 20 cm perpendicular to the boil again , covering a reference of 1 square centimeter to measure the area affected by the diabetic foot ulcer syndrome.

- Every 7 days of initiation of therapy in the clinic consultation wounds measured and circulation and comment the following:

- Ulcer area in square millimeters .

- Coloring of the ulcer .

- Type of exudate ; turbid serous .

- Type of tissue involved in the ulcer to its depth. If any patients have increased intensity of the signs and symptoms of diabetic foot syndrome, classified as a major step on the scale of ulcers Classification System of the University of Texas, perform analysis and comprehensive treatment will be redefined according to the suggestions of ulcer classification system of the University of Texas.

Material cleaning the ulcer :

Ingredient 1: Preparation of spray application of chlorhexidine gluconate 0.125% .

Ingredient 2: Preparation of spray application of sterile deionized water .

Method of application of ingredients as described previously .

Method of randomization : is effected by assigning random numbers balanced computer, the code will be assigned to each of the ingredients which have identical presentations , they will balance to the sample size . The code will not be known by the patient, observer and analyst. Only be known by one of the advisors.

Statistical methods :

The description of the data, in the case of non-numerical variables will be performed by reporting proportions and confidence interval of 95 % (95 %) in the case of numerical variables, the description will be made based on averages and standard deviation or medians and Q1- Q3 range , depending on the result of the Kolmogorov-Smirnov test to evaluate the Gaussian distribution of the data.

Comparison of numerical variables were not performed by Chi square test . Comparison of the rates of reduction in the size of ulcers of diabetic foot syndrome for both treatments will be based on the t test for independent samples or by Kruskal- Wallis test , depending on data distribution .

In all cases be considered as the significance level alpha value <0.05 .


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date December 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Indistinct gender

- Patients over 18 years with Diabetes Mellitus and

- Submit ulcer from diabetic foot syndrome not involving tendon , capsule or bone.

- With proper state of vascular perfusion.

Exclusion Criteria:

- Ulcers in patients with interdigital or difficult to measure the affected surface areas.

- Patients not be located at follow-up or wish to stop participating in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
chlorhexidine gluconate
chlorhexidine gluconate spray of 0.125% . Application in the area of the ulcer every 24 hours for six weeks
Other:
deionized water
application every 24 hours six weeks

Locations

Country Name City State
Mexico Hospital General Leon Leon Guanajuato

Sponsors (2)

Lead Sponsor Collaborator
Universidad de Guanajuato National Council of Science and Technology, Mexico

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Unlike the ultimate determinations for the initial surface of the ulcer obtained in square millimeters. Total ulcer area shall be measured by drawing software AUTOCAD LT 2014 , which defines the edges of the ulcer surface area in each of the two photographs , to take an average of the measure and get a value to be analyzed, that value is checked against the reference area of 1 square centimeter to increase measurement accuracy . 15 days No
See also
  Status Clinical Trial Phase
Completed NCT04332679 - Non-resorbable Membranes Versus Titanium Meshes and Resorbable Membranes N/A
Completed NCT00187759 - Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection N/A
Completed NCT01557426 - Soft Tissue Ultrasound of Infections Phase 1
Active, not recruiting NCT04257097 - Reinforced PTFE Meshes Versus Customized Titanium Meshes N/A
Enrolling by invitation NCT05826873 - Discharge Stewardship in Children's Hospitals N/A
Completed NCT04393909 - Improving Safety of Diagnosis and Therapy in the Inpatient Setting N/A
Active, not recruiting NCT02595047 - Autologous Prefabrication of Body Surface Tissues/ Organs(e.g. Joint) N/A
Completed NCT01790698 - Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).
Completed NCT00785200 - MRSA Colonization and Control in the Dallas County Jail N/A
Completed NCT00426933 - Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections Phase 2
Terminated NCT00102947 - Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections Phase 4
Completed NCT00451386 - Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036) Phase 2
Completed NCT03643952 - Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029) Phase 2
Recruiting NCT02979951 - Fosfomycin i.v. for Treatment of Severely Infected Patients
Completed NCT02600871 - Skin and Soft Tissue Infection (SSTI) Study Phase 4
Completed NCT00303589 - A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections Phase 2
Completed NCT04286334 - Three-dimensional Bone Regeneration Using Custom-made Meshes With and Without Collagen Membrane N/A
Recruiting NCT05471908 - Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial N/A
Withdrawn NCT03982030 - Dalbavancin Outpatient Pilot Phase 4
Terminated NCT00430937 - Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections Phase 3